Moderna, Inc.

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-14 pm EST			Pre-market 08:45:07 am
34.46 ^USD	-1.96%		34.86	+1.15%

12:22pm	Morgan Stanley Cuts Price Target on Moderna to $38 From $70, Keeps Equalweight Rating	MT
11:12am	Analyst recommendations: Adobe, Intuit, XPO, Netflix, Tesla...

Berenberg Initiates Moderna at Hold, With $42 Price Target

November 19, 2024 at 04:55 am EST

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Moderna, Inc.

Morgan Stanley Cuts Price Target on Moderna to $38 From $70, Keeps Equalweight Rating	06:22am	MT
Analyst recommendations: Adobe, Intuit, XPO, Netflix, Tesla...	05:12am
Leerink Partners Adjusts Moderna Price Target to $27 From $31, Maintains Underperform Rating	Jan. 14	MT
Stocks Gain Pre-Bell Ahead of Latest PPI Report; Asia, Europe Strong	Jan. 14	MT
MODERNA : Oddo BHF lowers its target price	Jan. 14	CF
Moderna, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 03:45 PM	Jan. 13
Stocks end mixed as US yields stay elevated	Jan. 13	RE
Health Care Climbs Amid Deal Activity - Health Care Roundup	Jan. 13	DJ
Equities Close Mixed as Traders Await Inflation Data, Bank Earnings	Jan. 13	MT
Equities Close Mixed as Traders Await Inflation Data, Bank Earnings	Jan. 13	MT
Sector Update: Health Care Stocks Rise Late Afternoon	Jan. 13	MT
US Equities Markets End Mixed Monday as Traders Await Key Data, Earnings	Jan. 13	MT
Equities Mixed Intraday as Markets Await Bank Earnings, Inflation Data	Jan. 13	MT
Sector Update: Health Care Stocks Gain Monday Afternoon	Jan. 13	MT
US Benchmark Stock Indexes Mixed as Magnificent 7 Stocks Decline	Jan. 13	MT
Top Midday Stories: Moderna Shares Fall After 2025 Revenue Guidance Cut; Cleveland-Cliffs Reportedly Teams Up With Nucor in Potential Bid for US Steel	Jan. 13	MT
Moderna Shares Tumble After 2025 Revenue Guidance Cut	Jan. 13	MT
RBC Capital Adjusts Price Target on Moderna to $40 From $50	Jan. 13	MT
Moderna Lowers Full-Year Revenue Outlook, Plans to Cut Cash Costs By $1 Billion	Jan. 13	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	Jan. 13	MT
Sector Update: Health Care	Jan. 13	MT
Moderna: plans to cut costs by E1bn by 2025	Jan. 13	CF
Top Premarket Decliners	Jan. 13	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid Declining Rate Cut Hopes	Jan. 13	MT
Moderna Cuts 2025 Revenue Guidance; Shares Drop	Jan. 13	MT

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (97.4%); - grant revenue (1.4%); - revenue from collaboration agreements (1.2%). At the end of 2023, the group possessed a portfolio of 41 products in clinical development, of which 6 in phase III, 12 in phase II and 18 in phase I, and 5 products in preclinical development. Net sales are distributed geographically as follows: the United States (27.7%), Europe (19.8%) and other (52.5%).

Employees

5,600

Sector

Biotechnology & Medical Research

Calendar

2025-02-13 - Q4 2024 Earnings Call

More about the company